Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies

The incidence of cancer is growing all over the world (Ferlay et al., 2015). However, total mortality has been reduced in the last two decades because of a lot of strategies such as smoke fighting, vaccination campaigns, improvement in surgical and radiotherapy approaches (Gyawali et al., 2018), as well as early diagnosis of cancer and the introduction of new therapies (Zhang et al., 2016). There are currently over 700 different types of pharmacological treatments for cancer in the pipeline of the Food and Drug Administration (FDA) (Yu, 2016), and current knowledge of the biology of cancer means more promising therapeutic possibilities.

Source: Critical Reviews in Oncology Hematology - July 16, 2018 Category: Cancer & Oncology Authors: C ássia Rita Pereira da Veiga, Claudimar Pereira da Veiga, Ana Paula Drummond-Lage Source Type: research